SCHEDULE 13G/A 0001491072 XXXXXXXX LIVE 1 Ordinary Shares, $0.01875 par value 03/31/2025 0001809616 UNIVERSE PHARMACEUTICALS, INC. G9442G104 265 JINGJIU AVENUE JI'AN, JIANGXI, F4 343100 Rule 13d-1(b) Anson Funds Management LP TX 0 234374 0 234374 234374 N 1 IA PN Anson Management GP LLC TX 0 234374 0 234374 234374 N 1 HC OO Tony Moore X1 0 234374 0 234374 234374 N 1 HC IN Anson Advisors Inc. Z4 0 234374 0 234374 234374 N 1 FI CO Amin Nathoo Z4 0 234374 0 234374 234374 N 1 HC IN Moez Kassam Z4 0 234374 0 234374 234374 N 1 HC IN UNIVERSE PHARMACEUTICALS, INC. 265 Jingjiu Avenue, Jinggangshan Economic and Tech Dev Zone Ji'an, Jiangxi, China 343100 Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam For Anson Funds Management LP, Anson Management GP LLC and Mr. Moore: 16000 Dallas Parkway, Suite 800 Dallas, Texas 75248 For Anson Advisors Inc., Mr. Nathoo and Mr. Kassam: 181 Bay Street, Suite 4200 Toronto, ON M5J 2T3 Anson Funds Management LP is a limited partnership organized under the laws of the State of Texas. Anson Management GP LLC is a limited liability company organized under the laws of the State of Texas. Mr. Moore is a United States citizen. Anson Advisors Inc. is a corporation organized under the laws of Ontario, Canada. Mr. Nathoo and Mr. Kassam are each Canadian citizens. N IA FI To Come Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 234,374 Ordinary Shares held by the Fund. Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 0.98% of the outstanding shares of Ordinary Shares, which includes shares of Ordinary Shares underlying outstanding warrants (each, a "Warrant," and collectively, the "Warrants") held by Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam. This percentage is determined by dividing 234,374 by 23,880,348, which is the sum of: (i) 23,645,974 Ordinary Shares issued and outstanding, as reported in the Issuer's Annual Report on Form 20-K filed with the Securities and Exchange Commission (the "SEC") on April 29, 2025; and (ii) 234,374 the number Ordinary Shares receivable by the Fund upon exercise of the Warrants. See Section 4(a) See Section 4(a) See Section 4(a) See Section 4(a) N Y Y Y N Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to [Name of institutional investor will be inserted here in your proof] is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. Anson Funds Management LP /s/ Tony Moore 05/15/2025 Anson Management GP LLC /s/ Tony Moore 05/15/2025 Tony Moore /s/ Tony Moore 05/15/2025 Anson Advisors Inc. /s/ Amin Nathoo 05/15/2025 /s/ Moez Kassam 05/15/2025 Amin Nathoo /s/ Amin Nathoo 05/15/2025 Moez Kassam /s/ Moez Kassam 05/15/2025